logo-loader
viewAdvanced Oncotherapy PLC

Total Voting Rights

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;font-weight:bold;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:70.9pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:106.3pt;text-align:justify;text-indent:-35.4pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:5.0cm;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:177.2pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}strong{font-family:"Times New Roman","serif";}em{font-family:"Times New Roman","serif";}p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}acronym{font-family:"Times New Roman","serif";} address{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-div:italic;}cite{font-family:"Times New Roman","serif";}code{font-family:Consolas;}dfn{font-family:"Times New Roman","serif";}samp{font-family:Consolas;}tt{font-family:Consolas;}var{font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .mw{size:595.3pt 841.9pt;margin:2.0cm 42.45pt 49.65pt 42.55pt;}div.mw{}p.nt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: right}span.nr{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.nu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; text-align: center}span.np{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.nv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";}span.nm{font-family:"Calibri","sans-serif"}p.nw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center} p.nx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.ny{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align:justify}span.nk{font-family:"Calibri","sans-serif"; color:black}p.nz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.ni{font-family:"Calibri","sans-serif"; color:#0D0D0D}table.oa{width:489.05pt;margin-left:-12.5pt;border-collapse:collapse}td.nf{width:230.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.ob{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 7.1pt}td.ne{width:237.25pt;padding:0cm 5.4pt 0cm 5.4pt}p.oc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: right} p.od{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";margin-left:7.1pt}span.nd{font-family: "Calibri","sans-serif"}p.oe{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}span.of{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"}p.og{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify; text-autospace: none}span.mz{font-family:"Calibri","sans-serif";color:black}span.oh{font-family:"Times New Roman","serif";font-family: "Calibri","sans-serif"; font-weight: bold} /**/
RNS Number : 2247O
Advanced Oncotherapy PLC
30 September 2019
 

30 September 2019

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Total Voting Rights

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 230,228,494 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 230,228,494.

 

The above figure of 230,228,494 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For the avoidance of doubt, the above figure excludes the 7,364,162 New Ordinary Shares to be allotted, issued and admitted to trading on AIM on or around 7 October 2019, being the final tranche of the equity fundraise as detailed in the announcement released earlier today.

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Joint Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 20 7601 6100



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 7980 54 1 893 / Mob: +44 7876 741 001

 

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVREAKNEDEDNEFF

Quick facts: Advanced Oncotherapy PLC

Price: 38

Market: LSE
Market Cap: £90.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17